Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 2/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 5/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | GRM5 | P41594 | 1/20 | 0.34 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.34 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.34 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29317714 | 0.90 | CYP2D6 (0.44) | HSD11B1EPHX2CYP2D6CYP1A2ALOX15 | |
| SCHEMBL18701846 | 0.84 | HSD11B1 (0.50) | HSD11B1EPHX2CYP2D6CYP1A2OPRM1 | |
| SCHEMBL29317721 | 0.84 | EPHX2 (0.36) | HSD11B1EPHX2CYP2D6CYP1A2ALOX15 | |
| SCHEMBL18702006 | 0.81 | HSD11B1 (0.59) | HSD11B1EPHX2CYP2D6CYP1A2GRM5 | |
| SCHEMBL29317699 | 0.78 | EPHX2 (0.39) | HSD11B1EPHX2CYP2D6HRH3KCNH2 | |
| SCHEMBL22959553 | 0.78 | HSD11B1 (0.46) | HSD11B1EPHX2CYP2D6CYP1A2KCNH2 | |
| SCHEMBL16591634 | 0.77 | OPRM1 (0.38) | HSD11B1CYP2D6CYP1A2ALOX15OPRM1 | |
| SCHEMBL23724098 | 0.77 | CYP1A2 (0.47) | HSD11B1EPHX2CYP2D6CYP1A2CYP3A4 | |
| SCHEMBL18701923 | 0.77 | HSD11B1 (0.44) | HSD11B1EPHX2HRH3 | |
| SCHEMBL25904153 | 0.76 | ALOX15 (0.48) | HSD11B1EPHX2CYP2D6CYP1A2ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240238425-A1 | HSD17B13 Inhibitors and/or Degraders | PFIZER INC. (US) | 2024-07-18 | — | — | US | disclosed |
| US-20240238425-A1 | HSD17B13 Inhibitors and/or Degraders | PFIZER INC. (US) | 2024-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240238425-A1 | HSD17B13 Inhibitors and/or Degraders | HSD17B13, HSD17B3, HSD17B1 | HSD11B1 9/4885EPHX2 949/4885CYP2D6 114/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.